Overall, the results presented in this study shows that endosomal TLR agonists delivered through Qβ VLPs are an effective immunotherapeutic strategy for the activation of APCs (monocyte, pDC, mDC) leading to CD4 + and CD8 + T cell activation and potential anti-tumor immune responses (Fig. 8). This evidence concerns the gene CD8A and neoplasm.